Press release

DSM is positioned for strong EBITDA growth and increases dividend

Heerlen, NL, 20 Feb 2013 06:30 CET

  • DSM reports a solid Q4 with EBITDA of €243 million
  • EBITDA full year 2012 of €1,109 million with growth in all clusters, except for caprolactam
  • Robust performance of Life Sciences driven by Nutrition
  • Materials Sciences performed well, except for caprolactam
  • Strong cash generation from operating activities of €730 million in 2012
  • Dividend increase proposed to €1.50 per ordinary share
  • Outlook 2013: moving towards EBITDA of €1.4 billion

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “In the context of challenging macro-economic conditions, DSM delivered growth across all clusters in 2012, excluding caprolactam. Nutrition now represents more than 70% of total EBITDA and has become a high value, global business with attractive growth prospects across the full value chain.” 

The significant strategic progress we made during 2012 through our value creating acquisitions and the profit improvement initiatives we have taken leave us well positioned to achieve our long term objectives. In 2013 we will focus on the operational performance and integration of the acquisitions we completed in 2012 with special attention to capturing synergies. We expect strong EBITDA growth in 2013, moving towards €1.4 billion. The Board’s proposal to increase the dividend for the third consecutive year is testament to the stronger DSM we have built in recent years, with more stable growth and profitability going forward.” 

Key figures

Q4 2012 Q4 2011 +/- in € million FY 2012 FY 2011 +/-
      Continuing operations      
2,269 2,227 2% Net sales 9,131 9,048 1%
243 293 -17% Operating profit before depreciation & amortization (EBITDA) 1,109 1,296 -14%
204 193   Nutrition 793 735  
13 11   Pharma 39 36  
52 43   Performance Materials 280 293  
14 79   Polymer Intermediates 129 380  
-9 -17   Innovation Center -38 -57  
-31 -16   Corporate Activities -94 -91  
120 166 -28% Operating profit (EBIT) 635 866 -27%
      Discontinued operations      
      Net sales   145  
      Operating profit before depreciation & amortization (EBITDA)   29  
      Operating profit (EBIT)   29  
      Total DSM      
2,269 2,227 2% Net sales 9,131 9,193 -1%
243 293 -17% Operating profit before depreciation & amortization (EBITDA) 1,109 1,325 -16%
75 118 -36% Net profit before exceptional items 437 615 -29%
-54 -33   Net result from exceptional items -149 199  
21 85 -75% Net profit 288 814 -65%
      Net profit per share in €:      
0.43 0.71 -39% before exceptional items, continuing operations 2.58 3.53 -27%
0.11 0.53 -79% including exceptional items, total DSM 1.68 4.86 -65%
      core earnings per share 2.78 3.66 -24%

You can find the press release in full, including financial statements, below.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864

This site uses cookies to store information on your computer.

Learn more